Daiichi will invest 1.1 billion Chinese yuan ($152 million) to build a new antibody-drug conjugate (ADC) manufacturing facility in Shanghai, the Japanese pharma said (Chinese), on the heels of ...
The “scientific trailblazer” behind Daiichi Sankyo’s blockbuster ADC medicines, Toshinori Agatsuma, has passed away, the company said Monday.
Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the ...